Login or Register to make a submission.

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.
  • I registered in Congress before submitting the article.
  • The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
  • The submission file is in OpenOffice, Microsoft Word, or RTF document file format.
  • Where available, URLs for the references have been provided.
  • The text is single-spaced; uses a 12-point font; employs italics, rather than underlining (except with URL addresses); and all illustrations, figures, and tables are placed within the text at the appropriate points, rather than at the end.
  • The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines.

Author Guidelines

  1. Overview

Date a



Dec 20, 2022

Abstract Submission Deadline

Jan 05, 2023

Abstract Modification and Withdrawal Deadline

Jan 20, 2023

Final Abstract Status Notification

Jan 25, 2023

ePoster Upload Deadline

Feb 2-4, 2023

ISRO 2023

a All deadlines are 11:59 PM Tehran time (UTC + 3:30)


  1. Submission Regulations
  • Abstract submission deadline for ISRO 2023 is on December 20, 2022.
  • Abstracts must be submitted online via the
  • In case of abstract withdrawal, please submit your requests in writing via email to by January 25, 2022, with your submission ID number(s).
  • For any questions regarding the online submission process, please email
  1. Aim and Scope

3.1. Clinical abstracts:

  • Breast cancer
  • CNS tumors
  • Cancer management in COVID-19 era
  • Cancer screening
  • Endocrine and neuroendocrine tumors
  • Gastrointestinal cancers
  • Genitourinary cancers
  • Gynecology cancers
  • Head and neck cancers
  • Hematological malignancies
  • Lung cancers
  • Palliative care
  • Psyco-oncology
  • Pediatric tumors
  • Sarcoma
  • Skin cancers

3.2. Physics abstracts:

3.3. Radiobiology abstracts:

  • Normal tissue radiobiology
  • Tumor radiobiology
  • Immuno-radiobiology
  • Microenvironment

3.4. RTT abstracts:

  1. Criteria for acceptance

4.1. Originality: By submitting an abstract intended for presentation at ISRO 2023, the first author (= presenter) warrants that the materials have not been previously published in any publication (in peer review setting) before February 15, 2023.

4.2. Accepted manuscript formats

  • Original research
  • Systematic review
  • Meta-analysis
  • We will not consider:
    • Reviews
    • Case reports/case series
    • Hypothesis or proposal papers
    • Letters, commentaries, or essays
    • Opinion pieces
    • Policy papers
    • Clinical practice guidelines
    • Any other type of secondary literature
    • Monographs

4.3. Abstract structure

  • Author names and affiliations should not be present in the abstract title and abstract content as the abstract must be blinded for review.
  • The title of the abstract should include significant keywords that reflect the content of the abstract
  • Abstracts must not exceed 350 words. Deduct 50 words for each table, graphs or figures included. For example, with two figures, the maximum word count is 250.
  • Images are not permitted as they do not reproduce well. Brief and clear tables, graphs, and figures are accepted (maximum of 1 page on US Letter, 8.5 x 11-inch paper).
  • The abstract is presented in an intelligible fashion and is written in standard English
  • The abstract must include the main headings of Background and Objectives, Methods, Results, and Conclusions
  • Methods cover the main experiments and analysis (if any)
  • Results cover the findings on primary (and secondary, if any) objective
  • Conclusions are presented in an appropriate fashion and are supported by the data
  • Use generic terms for drug names
  • Standard abbreviations may be used without definition. Nonstandard abbreviations should be kept to a minimum and placed in parentheses after the first use of the word or phrase
  • Use International System (SI) for units


  1. Review Process
  • Each abstract will be blinded and scored by up to two reviewers.
  • The reviewers are selected based on the abstract category (clinical, physics, radiobiology, RTT)
  • Abstracts will be accepted on the basis of scientific merit and originality.
  • Overall, bear in mind that your abstract will be rated according to the following criteria:
    • is the design of the study valid?
    • are the methods appropriate?
    • what is the significance of the results?


Section default policy

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.